RxDoctor Payments DataLook up a doctor →

Lisa Clairmont

Nurse Practitioner · Bismarck, NDNPI 1174611370

Payments from drug & device makers

$14,704in general payments, 2019–2025

Across 386 payments — averaging $38.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catalyst Pharmaceuticals, Inc.$3K
  • Acadia Pharmaceuticals Inc$3K
  • Biogen$2K
  • AbbVie$1K
  • AstraZeneca$524
  • Pfizer$474
  • plus $4K from 51 others

What the payments were for

  • Consulting fees$2,87120%
  • Speaking & faculty fees$2,01414%
  • Travel & lodging$1,3809%
  • Food & beverage$8,43857%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,704 in reported general payments places this provider in the 95th percentile of 455 nurse practitioner providers in North Dakota.

See all nurse practitioner providers in North Dakota

Medicare billing

Part B allowed, 2024
$29,628
Medicare patients
229
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate63$254,797
BetaseronInterferon Beta-1b13$127,812
VumerityDiroximel Fumarate13$114,474
Kesimpta PenOfatumumab12$103,146
RytaryCarbidopa/Levodopa103$101,839
CopaxoneGlatiramer Acetate14$84,926
FingolimodFingolimod Hcl11$79,397
GocovriAmantadine Hcl19$46,718
Aimovig AutoinjectorErenumab-Aooe58$42,535
Carbidopa-LevodopaCarbidopa/Levodopa479$30,583
QuliptaAtogepant22$28,871
UbrelvyUbrogepant23$24,865
Emgality PenGalcanezumab-Gnlm36$24,856
Ajovy AutoinjectorFremanezumab-Vfrm23$17,733
Carbamazepine ErCarbamazepine67$9,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$3,088$254,79763 claims
BayerBetaseron$13$127,81213 claims
BiogenVumerity$1,993$114,47413 claims
Amneal Pharmaceuticals LLCRytary$137$101,839103 claims
Teva Pharmaceuticals USA, Inc.Copaxone$11$84,92614 claims
AbbVieQulipta, Ubrelvy$1,108$53,73545 claims
MDD US Operations, LLCGocovri$347$46,71819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 nurse practitioner providers in North Dakota.

Other nurse practitioner in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →